Anteris Technologies Global Corp.
NASDAQ:AVRMedical - Devices
-$0.02 today
- Market cap
- $496.24M
- Beta
- 0.73
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$4.04
Volume 1.26M
Average 1.18M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Anteris Technologies Global Corp.
NASDAQ:AVR
Intrinsic Alpha fair value
Locked
Current Price
$5.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -15.8% | +154.1% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -15.8% over three years. Forward estimates point to Revenue at +154.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Medtronic plc NYSE:MDT | $131.58B | $102.86 | Undervalued | 21.1 | +2.84% |
Boston Scientific Corporation NYSE:BSX | $64.27B | $44.34 | Undervalued | 19.0 | -55.50% |
Edwards Lifesciences Corporation NYSE:EW | $61.61B | $107.15 | Overvalued | 46.2 | +23.53% |
LivaNova PLC NASDAQ:LIVN | $5.03B | $91.32 | Undervalued | 40.5 | +72.35% |
Artivion, Inc. NYSE:AORT | $931.88M | $19.10 | Overvalued | 86.7 | -57.96% |
Continue the stock analysis
Jump to another research area for this company.